How often H. pylori comes back and what affects its return.

Recurrence of H Pylori : Incidence and Influential Factors in Sohag Government.

This project will follow adults aged 18–75 who were treated for H. pylori to see how often the infection returns and which eradication regimens lower that risk.

Quick facts

• Phase: Not applicable
• Study type: Interventional
• Enrollment: 100 (estimated)
• Ages: 18 Years to 75 Years
• Sex: All
• Sponsor: Sohag University (Academic / other)
• Locations: 1 site (Sohag)
• Trial ID: NCT07045857 on ClinicalTrials.gov

What this trial studies

The study follows adults with confirmed H. pylori infection who completed medical eradication therapy and tracks them over time for recurrence. Participants will undergo periodic testing (urea breath test, stool antigen, or endoscopy/biopsy when indicated) and clinical assessments to document any return of infection. Investigators will collect data on the eradication regimen used, medication adherence, demographics, and comorbidities to identify factors associated with recurrence. The primary outcomes are recurrence rate and differences in recurrence between treatment approaches.

Who should consider this trial

Good fit: Adults 18–75 with a confirmed H. pylori infection who have received standard eradication therapy, have symptoms such as dyspepsia or peptic ulcer disease, and have normal liver, kidney, and blood test results.

Not a fit: Patients with recent use of proton pump inhibitors, H2 blockers, bismuth, or antibiotics within four weeks, active malignancy, severe unstable comorbidities, or recent significant gastrointestinal bleeding are unlikely to benefit or be eligible.

Why it matters

Potential benefit: If successful, the results could help doctors choose treatments and follow-up plans that reduce H. pylori coming back for future patients.

How similar studies have performed: Many prior studies have measured H. pylori recurrence and compared eradication regimens, so this approach is consistent with existing research though local results may vary.

Eligibility criteria

Inclusion Criteria:

* Age: 18-75 years old.
* H. pylori infection: Confirmed by endoscopy, biopsy, or non-invasive tests (e.g., urea breath test, stool antigen test).
* Symptoms: Presence of dyspepsia, peptic ulcer disease, or other H. pylori-related symptoms.
* Laboratory tests: Normal liver and kidney function, and no significant abnormalities in blood counts.

Exclusion Criteria:

* Patients receiving eradication therapy in the past taking proton pump inhibitors,, H2 blockers ,,bismuth ,, antibiotics or other medications that interfere with the result of the examination in the recent 4 weeks.
* Gastrointestinal disorders: Severe gastrointestinal disorders (e.g., gastric cancer, inflammatory bowel disease ,gastric or duodenal ulcer with current or recent bleeding , or clinical significant gastrointestinal bleeding within 4 weeks of randomization).
* Malignancies: Active or recent malignancies.
* Severe comorbidities: Unstable or severe comorbidities (e.g., heart failure, liver cirrhosis).

Where this trial is running

Sohag

• Sohag University Hospital — Sohag, Egypt (Recruiting)

Study contacts

• Study coordinator: Thomas W Thabet, Resident

Conditions H. Pylori Infection